Introduction
One mechanism for pleiotropic drug-resistance is the suppression of drug-induced apoptosis downstream of drug-induced cellular damage (Dive and Hickman, 1991; Fisher, 1994) . Proteins of the Bc1-2 family are thought to be principal participants in a cellular decision-making process regarding whether a cell in a speci®c context will live or die. This decision is presumably based upon the receipt of incoming signals emanating from cellular damage and micro-environmental factors. The Bc1-2 family is comprised of both anti-and pro-apoptotic proteins (Adams and Cory, 1998) . The anti-apoptotic members (e.g. Bc1-2, Bc1-x L and Bcl-w) contain four Bc1-2 homology (BH) domains and a hydrophobic C-terminal domain (TM) that can tether them to internal membranes. The pro-apoptotic members of this family are further subdivided into those with BH-1, BH-2, BH-3 domains and the TM (e.g. Bak, the focus of this study, Bax and Bok), and those with only the BH-3 domain with or without a TM (e.g. Bid, Bim, Bad and Bik). Several mechanisms are proposed to regulate Bc1-2 family protein function(s) including transcriptional control (Miyashita and Reed, 1995) , protein ± protein interactions (Oltvai and Korsmeyer, 1994) , translocation , phosphorylation (Datta et al., 1997 , Deng et al., 2001 , proteolysis (Gross et al., 1999) and conformational change (Griths et al., 1999; Desagher et al., 1999) .
Structural studies suggest that the BH-1 and BH-2 domains of Bc1-x L form a hydrophobic cleft into which the BH-3 domains of certain other family members may insert (Muchmore et al., 1996) . The ratio of homodimers to heterodimers within the Bc1-2 family has been proposed as a determinant of cell fate, the so-called`rheostat model ' (Oltvai and Korsmeyer, 1994) , although this is unlikely to be a universal mechanism of regulation (Knudson and Korsmeyer, 1997 ). An emerging consensus suggests that cell damage signals promote changes in the N-termini of several pro-apoptotic Bc1-2 family proteins. In the case of Bid, this is thought to occur when its N-terminus is cleaved by caspase-8 to generate tBid (Gross et al., 1999) and both Bcl-2 and Bc1-x L can be converted from anti-apoptotic to pro-apoptotic proteins by caspase-mediated cleavage of their N-termini (Cheng et al., 1997; Clem et al., 1998) .
However, a damage signal induced change in the Ntermini of Bak and Bax can occur in the absence of protein cleavage (Griths et al., 1999; Desagher et al., 1999; Taylor et al., 2000) . We reported previously that the exposure of an otherwise hidden epitope at the N-terminus of Bak in T-lymphoma cells occurred in response to mechanistically diverse pro-apoptotic stimuli and that this occurred before morphological signs of apoptosis (Griths et al., 1999) . We inferred that a conformational change in the Bak N-terminus and/or the loss of an N-terminal binding protein was associated with the integration of a range of disparate damage signals and re¯ected the activation of Bak. A change in the N-terminus of Bax, interpreted as change in protein conformation, has also been described in several cell types after various death-inducing stimuli (Griths et al., 1999; Desagher et al., 1999; Murphy et al., 2000; Gilmore et al., 2000) . In HeLa cells, this Nterminal change in Bax was dependent on the binding of uncleaved Bid, and was followed by Bax oligomerization and insertion into the outer mitochondrial membrane (Eskes et al., 2000) . A similar scenario has been recently described for Bak; engagement of the TNFR1/Fas death receptors resulted in production of tBid that promoted Bak oligomerization in the mitochondrial membrane (Wei et al., 2000) . The oligomerization of Bax and Bak in the mitochondrial membrane was associated with the release of cytochrome c (Eskes et al., 2000; Wei et al., 2000) . Its exit route is not yet clear. The opening of putative channels consisting of, or modulated by the pro-apoptotic Bc1-2 family members is suggested (Schendel et al., 1997) , although this remains contentious. Cytoplasmic cytochrome c binds to the`apoptosome' protein complex that promotes activation of a caspase cascade to orchestrate cellular disassembly (Kluck et al., 1997; Green and Reed, 1998) . Taken together these data imply that changes at the N-terminus are critical events that activate the pro-apoptotic function(s) of Bc1-2 family proteins. In our studies of T lymphoma cell lines, Bak was constitutively bound to Bc1-x L in untreated cells and resident in mitochondrial membranes before and after cell damage (Griths et al., 1999) . We demonstrate here that a second damageinduced change in Bak occurs subsequent to Nterminal exposure that is re¯ected by a change in the central BH-1 region of the molecule.
This second change occurred in parallel with the release of Bc1-x L from Bak and immediately prior to, or concomitant with the release of cytochrome c from mitochondria.
Results
Cell damage promotes the exposure of second, central epitope in Bak that occurs after the exposure of the N-terminal epitope Experiments using Bak N-terminal epitope speci®c antibodies showed that the exposure of these epitopes was an event detectable early after cell damage and before any detectable morphological change associated with apoptosis. Using a monoclonal antibody raised to a peptide corresponding to aa 82 ± 135 of Bak (Ab-3), a region spanning the central BH-1 domain (Figure 1a ) a second damage-induced change in Bak was observed which was temporally separate to the change at the Bak N-terminus (Figure 1b,c) . In untreated CEM C7A cells neither Ab-1 (N-terminal) nor Ab-3 (BH-1 domain) had access to Bak (data not shown). Figure  1b shows that 4 h after treatment with the topoisomerase II inhibitor etoposide, the N-terminus of Bak became available for Ab-1 binding, but there was no Ab-3 bound. At this timepoint there were less than 5% apoptotic cells, and these were excluded from¯ow cytometric analysis by electronic gating. Six hours later, both Bak epitopes were exposed, as reported by the binding of both Ab-1 and Ab-3. Figure 1c shows the kinetics of these conformational changes up to 24 h after etoposide treatment of Jurkat and CEM C7A cells, demonstrating that the N-terminal region of Bak responds to etoposide damage ®rst, followed by a second change to expose the BH-1 domain of Bak. This sequence of events was also seen after treatment of CEM C7A cells with the general kinase inhibitor staurosporine (STS) (data not shown). We previously reported that etoposide treatment of Jurkat cells resulted in a decrease in the amount of Bak bound to Bc1-x L at 20 h (Griths et al., 1999) . We now show that at this time, 60% of cells contain Bak that binds both the N-terminal and BH-1 domain epitope speci®c antibodies (see Figure 1c) . Figure 2ai shows a series of immunoprecipitations using a polyclonal anti-Bc1-x L antibody performed at 4 h and 24 h after treatment of Jurkat cells with etoposide (10 mM). At 4 h, when the N-terminal epitope was exposed but the BH-1 domain epitope remained masked, there was no evidence that etoposide has induced the dissociation of Bak from Bc1-x L . By 24 h, when the BH-1 domain epitope was exposed in the majority of cells, a decrease in the binding of Bak to Bc1-x L was observed. Data from three independent experiments are presented as bar charts generated by densitometric analysis of immunoreactive bands in the immunoprecipitation experiments (Figure 2aii ). These show quantitatively that binding of Bak to Bc1-x L decreases with time after imposition of etoposide damage, to reach 50% by 24 h. This decrease correlated with exposure of the BH-1 domain as re¯ected by changes in Ab-3-associated immuno¯uor-escence (compare Figure 2a with Figure 1c ). These changes also correlated with the appearance of apoptotic cells; 24 h after exposure of Jurkat cells to 10 mM etoposide 53+6% cells were apoptotic (see Griths et al., 1999) . These data prompted us to examine the relationship in a single cell between Bak Ab-3 exposure and cytochrome c release from mitochondria (see Figure 4 below).
Immunoprecipitations were also conducted using Ab-3 to the BH-1 domain. In contrast to what we observed using Ab-1 (N-terminus) to immunoprecipitate Bak, where Bc1-x L was co-immunoprecipitated, no Bc1-x L could be retrieved at any time point in either control or etoposide-treated cells when the Bak Ab-3 antibody was used ( Figure 2b ). These data imply that Ab-3 competes with Bc1-x L for access to the same domain of Bak.
Bak is predominantly associated with intracellular membranes in lymphoma cells (Griths et al., 1999) . The interpretation of immunoprecipitation results such as those shown in Figure 2a is therefore complicated by the essential use of detergents which promote oligomerization and reciprocal binding of Bc1-2 family proteins . Bak has both a cytosolic and membrane location in primary tissues such as mouse liver ( Figure 2ci ) and we were able to examine its association with Bc1-x L in the absence of detergents. By processing cytosolic extracts of mouse liver through two consecutive steps of anity chromatography, we demonstrated that native Bak associates with Bc1-x L , even after reaction with antibodies speci®cally recognising the N-terminus domain of Bak ( Figure 2cii ). These data sustain the validity of the results obtained using detergent extracts of lymphoma cells (Figure 2ai ), in that they indicate a constitutive, strong association of Bak to Bc1-x L in resting conditions and when the N-terminus of Bak is occluded.
Effects of Bc1-x L overexpression on damage induced changes at the N-terminus and central BH-1 domain of Bak
The data presented in Figures 1 and 2 show that two changes in epitope availability occur in Bak after either Western blots for Bak and Bc1-x L after immunoprecipitation of Bak using the Ab-3 antibody (to the BH-1 domain) from either untreated cell lysates or from lysates of cells that had been treated with etoposide (10 mM) for 24 h. U = unbound fraction and B = bound fraction. (c(i)) shows the expression of Bak in subcellular fractions obtained from mouse liver. S20 and S2 indicate cytosolic fractions (containing also ER) obtained as supernatants after centrifugation at 20 000 and 10 000 g, respectively, while S3 is the supernatant of the standard wash of crude mitochondria at 10 000 g. P20 and P10 are the corresponding membrane-rich pellets obtained after centrifugation at 20 000 and 10 000 g, respectively, while M denotes the washed mitochondria. (c(ii)) shows the presence of Bak and Bc1-x L in the cytosolic fraction (S20) of mouse liver (load) and their co-elution from an anity column constructed with a polyclonal antibody to the N-terminus of Bak. The Western blots presented are representative of three independent repeat experiments etoposide or STS treatment, that Bak can bind to Bc1-x L before and after exposure of the Bak N-terminus by damage signals and that Bc1-x L to Bak binding is lost in parallel with Bak BH-1 domain exposure. We therefore examined whether either one or both changes in Bak could be modulated by overexpression of Bc1-x L . CEM C7A cells were transfected with Bc1-x L and analysed both by Western blotting that was quanti®ed by densitometry and by¯ow cytometric analysis using a pAb Bc1-x L . A clone was identi®ed (8H2) that expressed 1.4-fold more Bc1-x L than transfectants with vector only control (Neo) (Figure 3 ). This moderate overexpression of Bc1-x L delayed the onset of etoposide-induced apoptosis. In two repeat experiments, the percentage of apoptotic cells at 8 h after etoposide treatment (10 mM) was reduced from 20 to 7% in 8H2 cells compared to neo-control cells. The kinetics of both etoposide-induced conformational changes in Bak were then compared in 8H2 and neo control cell lines. The kinetics of the Bak N-terminal conformational change after etoposide treatment was unaltered by Bc1-x L overexpression. However, the time taken for 50% cells to expose their BH-1 domain of Bak was extended from 16 to 22 h by Bc1-x L overexpression (Figure 3b ). Thus, an increased level of Bc1-x L that had no eect on the exposure of the N-terminus of Bak, delayed the second change in Bak (BH-1 domain exposure) that occurred when there was the release of Bak from Bc1-x L .
Relationship between damage signal mediated exposure of the BH-1 domain of Bak and the release of cytochrome c from mitochondria
Given that the kinetics of damage-induced exposure of the Bak BH-1 domain and the appearance of apoptotic morphology seemed to be closely correlated, it was important to determine whether the exposure of the Bak BH-1 domain preceded, accompanied or followed the release of cytochrome c from mitochondria. The heterogenous onset of drug-induced apoptosis in CEM cells suggested that subcellular fractionation and Western blotting for cytochrome c would not be able to address this question satisfactorily. We therefore adopted a cell by cell approach. Untreated CEM cells and those treated for 4 h with STS or etoposide were dual stained for Bak BH-1 and cytochrome c and examined by confocal microscopy. Untreated cells showed a punctate distribution of cytochrome c with little, if any, positive staining for Bak BH-1 above the background (Figure 4a , left-hand panel inset). In the majority of treated cells that had an exposed Bak BH-1 domain, staining for cytochrome c was diuse and cytosolic and did not co-localize with Bak (Figure 4a ). However, it was possible to detect a small percentage of cells (55% of the total number of cells analysed, marked with arrows) in which the Bak BH-1 domain was exposed and co-localized with cytochrome c in a punctate mitochondrial distribution. No cells were seen with diuse cytochrome c without Bak BH-1 exposure. These data were corroborated by similar results using HT29 human colon carcinoma cells treated with STS (250 nM) overnight (Figure 4b ). Bearing in mind the rapidity and synchrony of cytochrome c release (Goldstein et al., 2000) , these observations indicate that the damage-induced exposure of Bak BH-1 occurs either immediately prior to or concomitantly with complete cytochrome c release from mitochondria.
Exposure of the BH-1 domain of Bak is detected in cells with apoptotic morphology but is not prevented by inhibition of caspases To further examine the relationship between the exposure by damage signals of the Bak BH-1 domain and the onset of morphological apoptosis, the nuclear morphology of cells that stained positively with Bak Ab-3 was examined by¯uorescence microscopy. Cells were detected with Bak BH-1 domain exposed and normal nuclear morphology. However, most cells that exhibited an exposed Bak BH-1 domain also contained Figure 5a ). However, the exposure of the epitope in the Bak BH-1 domain was not prevented by the pancaspase inhibitor ZVAD-fmk (50 mM). Flow cytometric analysis showed that the percentage of etoposide treated cells (50 mM for 24 h) able to bind Bak Ab-3 (to the BH-1 domain) was completely unaected by the presence of ZVAD (Figure 5bi ) although the latter suppressed cell death. The ecacy of ZVAD was demonstrated as it prevented the cleavage of caspase 3 (Figure 5bii ) and reduced the percentage of dead cells (assessed by trypan blue exclusion at 24 h) from 83% after etoposide treatment to 5% after treatment with etoposide and ZVAD-fmk.
Discussion
The induction of apoptosis by cellular damage requires the activation of an intracellular signalling cascade that is coupled to changes in proteins that control the survival of the cell. The Bc1-2 family of proteins plays a pivotal role in setting the threshold for survival. They may thus also lie close to a point where damage signals and survival signals are integrated. It is becoming clear that the pro-apoptotic proteins in this family are in a latent state in the unperturbed cell, requiring activating signals to initiate apoptosis. It is also suggested in several reports (Griths et al., 1999; Desagher et al., 1999; Taylor et al., 2000; Gilmore et al., 2000) that the N-terminus of these proteins represents an important locus for the conversion from protein latency to protein activity. For Bak, we previously showed that a change in its N-terminus was a prelude to apoptosis after disparate types of cell damage (Griths et al., 1999) .
How is the exposure of the N-terminus of Bak linked to its pro-apoptotic activity? This crystal structure of the BH3-only family member Bid suggested that its Nterminus might overlay its BH3 domain (the domain critical for promoting cell death), (McDonnell et al., 1999) . Cleavage of the N-terminus of Bid, observed after activation of caspase 8, is thus expected to expose the BH-3 domain. However, full length Bid can also promote apoptosis (Eskes et al., 2000) and this raises the possibility that exposure of its BH-3 domain could occur via mechanisms other than N-terminal cleavage. The recent elucidation of the Bax 3D structure showed that the mechanism whereby soluble Bax is maintained in an inactive state may dier from that proposed for Bid (Suzuki et al., 2000) . The C-terminus of Bax overlays its BH-3 domain and the N-terminus is ā exible region of the molecule in solution (Suzuki et al., 2000) . The model proposed for Bax activation is that a change in the C-terminus must occur to free the BH-3 domain to simultaneously allow Bax insertion to the mitochondrial membrane and the BH-3 mediated interaction with other proteins such as Bid or Bc1-x L . Given the sequence homology between Bax and Bak the assumption would be that this mechanism could also apply to Bak if it were constitutively located in the cytosol. Bak is indeed cytosolic in primary mouse liver (Figure 2c ) but in CEM T lymphoma cells, it is Bc1-x L binding that is likely to occupy the BH-3 domain of Bak rather than interference by the Bak C-terminus (Figure 2a) . Furthermore, Bak that is constitutively mitochondrial in CEM cells (Griths et al., 1999) would have its C-terminus buried into the mitochondrial membrane and not overlaying the BH-3 domain. We show here that when the N-terminus of Bak is unmasked after damage, Bc1-x L remains bound to Bak (Figure 2a ) and at this time there are no cells with apoptotic morphology. This necessarily implicates the existence of a second step in the activation of Bak. Using an antibody to an epitope of Bak (Ab-3) which included the central BH-1 domain (aa 82 ± 135), a second change was observed after the exposure of the N-terminus. It occurred in two T lymphoma cell lines (CEM C7A and Jurkat) (Figures 1 and 3 ) and in HT29 colon carcinoma cells (Figure 4b ) in response to damage from two mechanistically disparate damaging agents, etoposide or STS. The exposure of the BH-1 domain of Bak re¯ects either a change in Bak itself and/or a change in its binding partner Bc1-x L that may weaken its anity for Bak. The disassociation of Bc1-x L and Bak occurred when the BH-1 domain was exposed.
How does exposure of the BH-1 domain relate to the pro-apoptotic activity of Bak's BH-3 domain? The 3D structure for Bak is currently unavailable. However, studies of Bid, Bc1-x L and the Bc1-x L -Bak BH-3 heterodimer suggest that the proteins consist of bundled alpha-helices, where the BH-3 domain of Bak lies in a cleft formed by the BH-1 and BH-2 domains of the binding partner Bc1-x L (Sattler et al., 1997) . These predictions are borne out by mutagenesis of the BH-1, -2 and -3 domains of Bc1-2 family proteins, all of which have a role in governing the binding of pro-and anti-apoptotic Bc1-2 family proteins (Yin et al., 1998; Wang et al., 1998) . The coelution of cytosolic Bak and Bc1-x L from an anity column constructed with antibody that binds to the Nterminus of Bak (Figure 2c ) provides supporting evidence that these proteins associate in the absence of detergent. The idea that Bc1-x L is bound at or close to the BH-1 domain of Bak was suggested as no Bc1-x L could be co-immunoprecipitated using the Bak BH-1 domain speci®c antibody (Bak Ab-3, Figure 2b) . Furthermore, although, the kinetics of N-terminal exposure of Bak were the same in CEM 8H2 cells with increased expression of Bc1-x L as those with basal levels (neo control), this increase in Bc1-x L caused a signi®cant delay in the exposure of BH-1 domain (Figure 3 ). The inability of over-expressed Bc1-x L to prevent the exposure of the N-terminus of Bak favours a model in which at least two signals are required; one promotes the exposure of the N-terminus of Bak and further signals impact upon Bak and/or Bc1-x L to mediate their dissociation.
If the exposure of the BH-1 domain of Bak is relevant to its activation by damage signals it must not merely be an event occurring in cells after the cellular execution machinery has been engaged. A trivial explanation of Bak BH-1 exposure as a consequence of execution processes is ruled out for the following reasons; overtly apoptotic were excluded from¯ow (Figure 5a ). Thirdly, BH-1 domain exposure also occurred in the presence of the caspase inhibitor ZVAD-fmk, indicating that it is independent of eector caspase activation (Figure 5b ). Despite these considerations we have noted that the vast majority of cells that stained positively with Bak Ab-3 contained diuse cytosolic cytochrome c and condensed chromatin. This leads us to propose that drug-induced exposure of the Bak BH-1 domain exposure occurs immediately prior to, or concomitantly with complete cytochrome c release and little time elapses between these events and the condensation of chromatin.
In summary, we have found that two distinct changes in endogenous mitochondrial Bak occur in intact cells after cellular damage. The ®rst change is observed at the N-terminus and is unaected by association with Bc1-x L (Griths et al., 1999 ; Figures  1 and 2 ). The second change produces an opening of an epitope(s) in the Bak BH-1 domain and is coincident with the dissociation of Bak from Bc1-x L (Figures 1 and 2 ). This may be a process that is facilitated by the preceding changes at the N-terminus. Bc1-x L remain to be discovered, as does the exact consequence of the exposure of the BH-1 domain adjacent to the BH-3 domain of Bak. This is the subject of ongoing work.
Materials and methods

Antibodies
The following antibodies were used in this study: Bak Ab-1 (mouse mAb IgG 2 a, #AM03) raised against a peptide corresponding to N-terminal residues 1 ± 52; Bak Ab-3 (mouse mAb IgG 2 a, Calbiochem, #AM15) raised against an epitope encompassing the BH-1 domain (aa 82 ± 135). Bak pAb (Calbiochem, #66026E) was raised to the whole Bak protein (excluding the C-terminal TM domain); anti-Bc1-x L pAb (Transduction Laboratories, #B22630). The secondary antibodies used were either Goat anti-mouse IgG conjugated to FITC (Dako) or Goat Anti-rabbit IgG conjugated to Cy3 (Jackson Immunochemicals) for immuno¯uorescence; for immunoblotting, goat anti-mouse-HRP and goat anti-rabbit-HRP were used (Dako). Cytochrome c was detected using the SC7159 rabbit pAb antibody (Santa Cruz). Caspase 3 was detected with a rabbit pAb (H-2777) obtained from Santa Cruz).
Other reagents
All other reagents were purchased from Sigma Chemical Company except: phosphate-buered saline (PBS) (Oxoid); cell culture media and reagents (Gibco, Paisley, UK); DNA Overexpression of Bc1-x L is unable to in¯uence this change suggesting that a damage-induced signal impacts upon Bak rather than Bc1-x L . In the second step of the model, the dissociation of Bak and Bc1-x L occurs subsequent to the exposure of the N-terminus of Bak. Under conditions of Bc1-x L overexpression, this second change is delayed implying that a second signal(s) is received by the Bak/Bc1-x L heterodimer, which may either further activate Bak, and/or inactivate Bc1-x L to inhibit heteromerization. Exposure of the BH-1 domain of Bak occurs close to the time of cytochrome c release and chromatin condensation restriction and modi®cation enzymes (Boehringer Mannheim).
Cell culture
All of the cell lines used in this study were grown in RPMI 1640 medium supplemented with foetal bovine serum (FBS, 10% v/v) and L-glutamine (2 mM).
Drug treatment and analysis of apoptosis
Using the same methods as previously reported (Griths et al., 1999) we con®rmed that at 4 and 24 h after etoposide there was 1 and 81% apoptotic cells respectively; with STS treatment, there was 37 and 79% apoptosis respectively.
Preparation and manipulation of DNA bc1-x L cloned in pcDNA3 was a gift from Dr Sabina Cosulich. Cell lines with the bc1-x L construct stably integrated into the genome were generated using standard methods, adding G418 (400 mg/ml) 24 h after transfection and maintaining selection for 3 weeks.
Analysis of Bak-associated immunofluorescence by flow cytometry
Drug-induced exposure of the N-terminus and BH-1 domains of Bak was measured using epitope speci®c antibodies Bak Ab-1 and Bak Ab-3 respectively, exactly as described in Griths et al. (1999) .
Analysis of Bak, cytochrome c and nuclear morphology by fluorescence microscopy Untreated and CEM T lymphoma cells treated for 8 h with etoposide were ®xed and stained with Bak Ab-3 (see Griths et al. (1999) for methodology) prior to addition of Hoechst 33342 (1 mg/ml). Images were captured using a Zeiss Axioskop microscope equipped with an epi-illuminator and appropriate ®lters. In separate experiments, CEM cells were treated with STS for 4 h then ®xed and dual stained for Bak Ab-3 and cytochrome c. These samples were examined using an Ultraview confocal optical scanner with a Kr/Ar laser (Perkin Elmer Life Sciences, Cambridge, UK) mounted on a Olympus 1670 microscope (Olympus, London, UK). Images were acquired with an Ultrapix charge-coupled device digital camera and processed by using an Ultraview software package. Spatial co-localization of Bak and cytochrome c associated immuno¯uorescence was obtained by overlaying separately recorded images on a colour image using Adobe Photoshop. HT29 colon carcinoma cells were grown as monolayers on glass coverslips, treated overnight with STS (250 nM) and then ®xed, stained and analysed as above.
Immunoprecipitation and Western blotting
The immunoprecipitation of Bak or Bc1-x L were performed using methods detailed in Griths et al. (1999) . Densitometry of the Western blots after was carried out using a BioRad GS 700 scanning densitometer and analysed using Molecular Analyst Software (Bio-Rad). For Western blots of coimmunoprecipitated proteins, changes in the levels of BakBc1-x L binding were determined by comparing the density of the respective immunoreactive bands in drug-treated versus untreated control samples at each time point analysed. Percentage changes between treated and untreated cells were then normalised for dierences in the amounts of the directly immunoprecipitated protein. These measurements were performed in triplicate.
Separation of Bak and Bc1-x L by affinity chromatography Subcellular fractionation of mouse liver was carried out as follows. After soaking with ice-cold PBS, livers were cut with scissors and suspended in isolation medium (10 mM K-HEPES, 0.25 M mannitol, 1 mM EGTA, 0.2% BSA, pH 7.4), then homogenized with a Te¯on pestle homogenizer. After centrifugation at 600 g for 5 min, the supernatants were centrifuged at 20 000 g for 30 min at 48C to precipitate mitochondria and other membrane organelles. The supernatants containing cytosol were passed through a PD10 gel ®ltration column equilibrated with 10 mM K-HEPES, 0.2 mM EDTA, pH 7.4, adjusted to a protein concentration of about 3 mg/ml and then processed with two consecutive steps of immuno-anity chromatography. In the ®rst step, the cytosolic extract was loaded onto a column containing Sepharose beads covalently bound to peptides spanning residues 1 ± 36 of the Bak human sequence to remove any protein that may be constitutively associated with cytosolic Bak. The¯ow through contained most of the Bak and Bc1-x L , and was subsequently incubated for 1 h with 1 mg/ml of ammonium-sulphate puri®ed polyclonal antibodies raised in sheep against the same N-terminal peptides of Bak. The immuno-complex was trapped by slow loading onto a protein G HiTrap column (Supelco), which was subsequently washed with increasing KCl concentrations in 10 mM K-HEPES, pH 7.4. The elution fractions containing both Bak and Bc1-x L were collected and concentrated by ultra®ltration before Western blotting.
